Wird geladen...
Concizumab: a novel anti-TFPI therapeutic for hemophilia
Concizumab is a novel subcutaneous prophylactic therapy for hemophilia. It is a hemostatic rebalancing agent that binds to the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), one of the molecules that contributes to downregulation of coagulation thereby preventing TFPI from binding to and...
Gespeichert in:
| Veröffentlicht in: | Blood Adv |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7805331/ https://ncbi.nlm.nih.gov/pubmed/33570646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001140 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|